Recreating liver tumors as organoids for faster, more accurate drug screening

February 9, 2018, National University of Singapore
Liver cancer organoids amenable for personalized drug testing. Credit: Dr. Melanie Lee, Mechanobiology Institute Science Communications Unit.

Liver cancer is one of the top causes of cancer deaths globally, with a lack of approved treatments. A major challenge in developing effective drugs for liver cancer is that current preclinical tumor models do not accurately replicate features of the tumor and the tumor environment in humans, causing many potential drugs to fail in clinical testing.

To more accurately mimic these features, researchers have developed models of called patient-derived xenografts (PDX). Although these models provide a truer picture of how effective potential drugs would be in humans, they are also expensive and time-consuming to create. Growing these PDX cancer in culture would be more cost effective for drug screening. However, current attempts to culture these cells fail to reflect the 3-D structure and the tumor environment.

Led by Dr. Eliza Fong and Dr. Toh Tan Boon, an interdisciplinary team of researchers at the NUS Departments of Physiology and Biomedical Engineering, the Cancer Science Institute of Singapore, the Institute of Bioengineering and Nanotechnology, A*STAR and the National Cancer Center Singapore has now devised a new method to grow PDX cancer cells for use in drug testing.

As described in their recent paper in Biomaterials, this method involves growing the cells on synthetic 3-D scaffolds made of a plant-based porous hydrogel. The researchers engineered the spongy scaffolds with optimized biochemical and mechanical properties to help the liver cancer cells maintain their proper shape and function and grow as organoids.

After growing the organoids for one to three weeks, the team verified that the liver cancer cells in the organoids were alive and reproducing. Liver cancer cells usually contain specific genetic changes that are absent in normal liver cells. The researchers engineered organoids from PDX that were taken from 14 liver cancer patients. Most of the organoids retained the same key genetic changes that were in the source PDX cells. They also maintained an important feature of liver tumors called intra-tumor heterogeneity, in which distinct populations of liver cancer cells are present within the same tumor and affect its response to treatment. The presence of this feature was another advantage for drug screening that the organoids have over traditional cell culture methods, in which all cells are identical.

As a bioengineer, Dr. Fong finds the success of the engineered organoids to be particularly rewarding. "This study truly epitomizes the positive synergy we can achieve in growing patient tumors outside the body by marrying advances in tissue engineering with cancer biology," she says.

Another attractive feature is the small size of the 3-D scaffolds containing the organoids—a mere 100 microns. They can easily fit inside the well of a 96-well microtiter plate, a standard platform for high-throughput , which enables testing many drugs at the same time. Through this technology, one PDX can be used to produce tens to hundreds of such organoid-containing scaffolds. Combined with their ability to recapitulate the genetic features and heterogeneity of the original liver tumors, these tumor avatars have the potential to revolutionize the screening and development of liver cancer drugs.

Dr. Toh says, "Having a reliable platform to grow liver cancer patient-derived cells is a major step in personalized medicine as we can now use them for increased throughput drug sensitivity testing."

Dr. Hanry Yu, Professor of Physiology at NUS Medicine, says, "The spongy scaffolds developed to keep normal liver cells happy also preserve the important properties of liver cancer for drug testing. This allows patients to choose the best treatment based on the testing results on their own liver cancer cells."

Explore further: Patient-derived organoids may help personalize the treatment of gastrointestinal cancers

More information: Eliza Li Shan Fong et al, Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer, Biomaterials (2018). DOI: 10.1016/j.biomaterials.2017.12.026

Related Stories

Patient-derived organoids may help personalize the treatment of gastrointestinal cancers

January 17, 2018
A new BJS (British Journal of Surgery) review highlights the potential of 3D organoid models derived from patient cells to help personalize therapy for individuals with gastrointestinal cancers.

Researchers discover two-step process to thwart cancer cells

February 2, 2018
Scientists at the University of Delaware and the University of Illinois at Chicago have found a new way to kill liver cancer cells and inhibit tumor growth. First, they silence a key cellular enzyme, and then they add a powerful ...

'Mini liver tumors' created in a dish for the first time

November 13, 2017
Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published today in Nature Medicine, the tiny laboratory models of tumours were used ...

Team finds a potentially better way to treat liver cancer

October 12, 2017
A Keck School of Medicine of USC research team has identified how cancer stem cells survive. This finding may one day lead to new therapies for liver cancer, one of the few cancers in the United States with an incidence rate ...

Study suggests colon cancer cells carry bacteria with them when they metastasize

November 24, 2017
(Medical Xpress)—A team of researchers working at Harvard University has found evidence that suggests a certain type of bacteria found in colon cancer tumors makes its way to tumors in other body parts by traveling with ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

Recommended for you

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

Particle shows promise to prevent the spread of triple-negative breast cancer

May 18, 2018
USC researchers have pinpointed a remedy to prevent the spread of triple-negative breast cancer. Metastatic breast cancer is a leading cause of death for women. The findings appear today in Nature Communications.

Dilemma for cancer patients as life-saving meds are tied to vision loss

May 18, 2018
(HealthDay)—A newer type of cancer treatment may offer the chance of longer survival, but the drugs could also trigger new side effects, such as vision problems.

Polygenic scores to classify cancer risk

May 18, 2018
Polygenic risk scores could be useful to stratify the risk of several cancers among patients in medical centers, allowing for the potential discovery of new associations between genes, disease and secondary effects, according ...

A way to prevent pancreatic cancer from spreading post-surgery?

May 17, 2018
Scientists at Cold Spring Harbor Laboratory (CSHL) have solved a mystery about how pancreatic cancer spreads following surgery in patients whose tumor is successfully removed. After surgery, patients' typically experience ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.